Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › NK1 antagonists

NK1 antagonists

US Patent 7241798 · Granted Jul 10, 2007

Estimated economic value: $150,041,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Tricyclic compounds and their use as phosphodiesterase inhibitors2024
Tricyclic compounds and their use as phosphodiesterase inhibitors2022
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands2022
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors2022
Cyclic substituted imidazo[4,5-c]quinoline derivatives2021
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds2020
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands2020
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds2019
Pyrazolopyrimidine compounds2018
Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2018
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[22017
Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors2017